Peer-reviewed research
Every peer-reviewed study we cite across the compounds we track, gathered in one place and linked straight to its PubMed record. We summarize the literature and point you to it — we don't interpret it. Nothing here is an endorsement, an efficacy or safety claim, or dosing guidance. Everything is research use only.
Evidence reviews
Neutral, fact-checked summaries of the peer-reviewed literature per compound — every claim cited, every source linked. Research use only.
- What the research says about retatrutide Moderate evidence
A neutral summary of the peer-reviewed literature on retatrutide, an experimental triple-hormone-receptor agonist studied in early-phase human trials for obesity. Research use only.
- What the research says about BPC-157 and tissue repair Preclinical only
A neutral summary of the peer-reviewed literature on BPC-157, a peptide studied almost entirely in animal and in-vitro models for tissue repair. No controlled human trials exist. Research use only.
Every study we cite
72 studies across 24 compounds
BPC-157 3 studies
Retatrutide 3 studies
- Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial
- Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial
- Effects of once-weekly subcutaneous retatrutide on weight and metabolic markers: A systematic review and meta-analysis of randomized controlled trials
Tirzepatide 3 studies
- Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial
- Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial
- Tirzepatide as Compared with Semaglutide for the Treatment of Obesity
Semaglutide 3 studies
- Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial
- Efficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes: A Systematic Review and Meta-Analysis
- Safety of Semaglutide
TB-500 3 studies
Tesamorelin 3 studies
Cagrilintide 3 studies
- Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial
- Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity
- Development of Cagrilintide, a Long-Acting Amylin Analogue
Ipamorelin 3 studies
CJC-1295 3 studies
- Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults
- Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse
- Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions
Sermorelin 3 studies
- Sermorelin: a better approach to management of adult-onset growth hormone insufficiency?
- Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency
- Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males
NAD+ 3 studies
MOTS-c 3 studies
GHK-Cu 3 studies
Melanotan II 3 studies
PT-141 3 studies
Selank 3 studies
- Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission
- Selank, Peptide Analogue of Tuftsin, Protects Against Ethanol-Induced Memory Impairment by Regulating of BDNF Content in the Hippocampus and Prefrontal Cortex in Rats
- The Influence of Selank on the Level of Cytokines Under the Conditions of "Social" Stress
Semax 3 studies
- Semax, an ACTH(4-10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodents
- Semax and Pro-Gly-Pro activate the transcription of neurotrophins and their receptor genes after cerebral ischemia
- Semax peptide targets the μ opioid receptor gene Oprm1 to promote deubiquitination and functional recovery after spinal cord injury in female mice
Kisspeptin 3 studies
Epithalon 3 studies
AOD-9604 3 studies
Glutathione 3 studies
- Supplementing Glycine and N-Acetylcysteine (GlyNAC) in Older Adults Improves Glutathione Deficiency, Oxidative Stress, Mitochondrial Dysfunction, Inflammation, Physical Function, and Aging Hallmarks: A Randomized Clinical Trial
- Randomized controlled trial of oral glutathione supplementation on body stores of glutathione
- GlyNAC Supplementation Improves Glutathione Deficiency, Oxidative Stress, Mitochondrial Dysfunction, Inflammation, Aging Hallmarks, Metabolic Defects, Muscle Strength, Cognitive Decline, and Body Composition: Implications for Healthy Aging
Thymosin Alpha-1 3 studies
DSIP 3 studies
IGF-1 LR3 3 studies
No studies match that search. Try a compound name or study type.
A representative set of studies for each compound, linked straight to PubMed — not an endorsement or a claim that any result applies to human use. Read them and judge for yourself. pepmg sells nothing and gives no medical, dosing, or human-use guidance. Everything here is research use only.